Skip to main content
Fig. 3 | Pediatric Rheumatology

Fig. 3

From: Case report: novel NFKB2 variant associated with pediatric eosinophilic granulomatosis with polyangiitis (EGPA) in the COVID-19 pandemic

Fig. 3

The summary of four cEGPA cohort. a The clinical features of reported cohort. b The management strategies of cEGPA patients in 2009, 2013,2016 and 2018 cohort. GC: Glucocorticoids; MMF: Mycophenolate mofetil; HCQ: Hydroxychloroquine; Hydrea: Hydroxyurea; PE: Plasma exchange; IFX: Infliximab; RTX: Rituximab; OMA: Omalizumab; ADA: Adalimumab

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096